MLYS (Mineralys Therapeutics) Total Assets: $652.86 Mil (As of Mar. 2026)


MLYS Mineralys Therapeutics Inc MLYS
35 GF Score
Price $26.68
! 1 Warning Sign
View Full Analysis

What is Mineralys Therapeutics Total Assets?

Mineralys Therapeutics MLYS +1.27% 35 Total Assets is $652.86 Mil as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Mineralys Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $652.86 Mil.

During the past 12 months, Mineralys Therapeutics's average Total Assets Growth Rate was -33.00% per year. During the past 3 years, the average Total Assets Growth Rate was 6.10% per year. During the past 5 years, the average Total Assets Growth Rate was 138.50% per year.

During the past 6 years, Mineralys Therapeutics's highest 3-Year average Total Assets Growth Rate was 480.60%. The lowest was 6.10%. And the median was 146.80%.

Total Assets is connected with ROA %. Mineralys Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -23.94%. Total Assets is also linked to Revenue through Asset Turnover. Mineralys Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Mineralys Therapeutics  (NAS:MLYS) Total Assets Explanation

Total Assets is connected with ROA %.

Mineralys Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-157.356/( (661.806+652.862)/ 2 )
=-157.356/657.334
=-23.94 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Mineralys Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (661.806+652.862)/ 2 )
=0/657.334
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Mineralys Therapeutics Total Assets Related Terms

Mineralys Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Total Assets Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 11.13 114.44 251.64 205.90 661.81

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 354.94 335.72 599.95 661.81 652.86
MLYS
35GF Score
Mineralys Therapeutics Inc MLYS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Mineralys Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=646.693+15.113
=661.81

Mineralys Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=638.144+14.718
=652.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $652.86 Mil mean?
Mineralys Therapeutics (MLYS) has a Total Assets of $652.86 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Total Assets too high?
Mineralys Therapeutics' current Total Assets is $652.86 Mil. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Total Assets compare to VCEL and NRIX?
Mineralys Therapeutics' Total Assets of $652.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Total Assets is $652.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Total Assets of $652.86 Mil. The current Total Assets is $652.86 Mil. Mineralys Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Total Assets is $652.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score

Get the complete analysis for MLYS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.68
Price